Subsidiary of Changchun High-Tech Industry (000661.SZ) approved for clinical trial application for trivalent influenza virus split vaccine (BK-01 adjuvant)

19:11 13/10/2025

Changchun High-tech (000661.SZ) announced that its subsidiary, Baik Bio, has received a notice from the National Medical Products Administration regarding its...

Changchun High-Tech Industry (000661.SZ) announced that its subsidiary Changchun Bcht Biotechnology has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for its trivalent influenza split vaccine (BK-01 adjuvant), allowing it to conduct clinical trials for the prevention of epidemic influenza caused by various types of influenza viruses.

GF SEC(01776): "25 Guangfa 09" coupon rate is 1.99%

CEOVU (00798) spent a total of 1,029,000 Hong Kong dollars to repurchase 4.2 million shares on October 13th.

Zhongtai (600918.SH) approved for registration reply for issuance of additional shares.

GF SEC(01776): "25 Guangfa 09" coupon rate is 1.99%

CEOVU (00798) spent a total of 1,029,000 Hong Kong dollars to repurchase 4.2 million shares on October 13th.

Zhongtai (600918.SH) approved for registration reply for issuance of additional shares.